604
Views
3
CrossRef citations to date
0
Altmetric
Olgu Sunumları/Case Reports

Ketiyapin ile Tedavi Edilen Olfaktör Referans Sendromlu Bir Olgu Sunumu

Olfactory reference syndrome treated with quetiapine: a case

, , , &
Pages 246-248 | Received 29 Dec 2010, Accepted 15 Apr 2011, Published online: 08 Nov 2016
 

ÖZET

Olfaktör referans sendromu (ORS) kişinin kendi bedeninin çok kötü bir koku yaydığına ve bu kötü koku yüzünden insanların kendisi hakkında olumsuz fikirler taşıdığına inandığı, bununla ilgili aşırı bir zihinsel meşguliyet içinde olduğu, nadir görülen bir ruhsal bozukluktur. Literatürde pimozid ve risperidon ile tedavi edilmiş ORS'li olgular bildirilmektedir. Ancak ketiyapin ile tedavi edilen bir olguya rastlanılmamıştır. Olgumuzda vücudundan gaita kokusu yayıldığı ile ilgili hezeyanı bulunan bir hastanın ketiyapin ile tedavisi sunulmuştur.

ABSTRACT

Olfactory reference syndrome (ORS) is a rare disorder in which the affected person is excessively preoccupied by the concern that their body emits very unpleasant odors and believes people have negative reactions to this perceived fault. In literature, several ORS cases, successfully treated by pimozide and risperidone, have been reported, though no report was found about quetiapine-treated ORS. Here, we report a case treated with quetiapine involving a man who believed that he emitted the odor of feces.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.